<DOC>
	<DOCNO>NCT01487083</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety pomaglumetad methionil participant schizophrenia .</brief_summary>
	<brief_title>A Long-Term Study Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Participants clinically diagnose schizophrenia Female participant childbearing potential must test negative pregnancy study entry agree use single , effective , medically acceptable method birth control New participant must require initiation modification current antipsychotic treatment , indicate present clinical psychiatric status and/or treatment tolerability outpatient . Criterion apply participant roll feeder study ( NCT01328093 NCT01452919 ) Participants must consider reliable level understanding sufficient perform test examination require protocol , willing perform study procedures Participants must able understand nature study give informed consent Are currently enrol , discontinue within last 60 day , clinical trial involve investigational product ( IP ) nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study , except participant roll feeder study ( NCT01328093 NCT01452919 ) complete clinical trial pomaglumetad methionil Have current psychiatric diagnosis addition schizophrenia Have previously complete withdrawn study , study investigate pomaglumetad methionil predecessor molecule glutamatergic activity , except participant roll feeder study ( NCT01328093 NCT01452919 ) complete clinical trial pomaglumetad methionil Participants receive adequate treatment trial , opinion investigator , clozapine dos great 200 mg daily within 12 month prior study entry , receive clozapine month study entry Participants history inadequate clinical response antipsychotic treatment schizophrenia Participants , reason , consider danger , actively exhibit suicidal behavior Female participant pregnant , nursing , intend become pregnant within 30 day complete study Have know , uncorrected , narrowangle glaucoma Participants current history seizure disorder , leucopenia , uncontrolled diabetes , certain disease liver , renal insufficiency , uncontrolled thyroid condition serious unstable illness Participants electroconvulsive therapy ( ECT ) within 3 month study entry ECT time study Participants know medical history Human Immunodeficiency Virus ( HIV ) positive status Participants test positive ( 1 ) Hepatitis C virus antibody ( 2 ) Hepatitis B surface antigen ( HBsAg ) without positive Hepatitis B core total antibody Participants correct QT interval ( Bazett 's ; QTcB ) &gt; 450 msec ( male ) &gt; 470 msec ( female ) study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>LY2140023</keyword>
	<keyword>pomaglumetad methionil</keyword>
</DOC>